Former VP at F Hoffmann-La Roche AG
- M&A trends and developments in biopharma
- Recent decrease in biopharma M&A activity, discussing valuations and potential for more deals in H2 2021
- Competitive dynamics and relative portfolio gaps among Merck (NYSE: MRK), Bristol-Myers Squibb (NYSE: BMY), Gilead (NASDAQ: GILD), Biogen (NASDAQ: BIIB), Roche (VTX: ROG), Sanofi (PAR: SAN), Astellas (TYO: 4503) and J&J (NYSE: JNJ)
- Outlook for H2 2021 and beyond
Gain access to Premium Content
Submit your details to access up to 5 Forum Transcripts or to request a complimentary one week trial.